Stem cell apheresis prediction method generates accurate and immediate yield predictions

10-09-2006

A stem cell apheresis prediction method generates accurate and immediate yield predictions.

According to a study from Italy, "Stem cell collection is a standard procedure for the procurement of autologous grafts to rescue myelosuppression induced by high-dose treatments. Accurate prediction of collection yields may contribute to optimize planning and quality control of collection.

"Data of 313 autologous hematopoietic stem cell (AHSC) evaluable collections performed in 208 patients with hematologic and nonhematologic neoplasms from seven centers were prospectively analyzed to test the accuracy of yield predictions generated by a formula that required the input of peripheral blood (PB) CD34+ cell precount and desired PB volume to be processed."

"Data were matched in a standard linear regression, in a zero-point regression analysis and tested for prediction accuracy. Further 165 AHSC collections were analyzed on a single-centre basis, using yield predictions as reference standards," wrote L. Pierelli and colleagues at ASL Viterbo.

"Analysis showed high levels of correlation between measured collection yields (my) and predictions (py) (R=0.85; p=0.000000) as well as high degree of prediction accuracy (my vs. py at paired t-test: p=0.114781; median my/py ratio=1.23).

"Analysis of additional 165 AHSC collections on a single-center basis showed that the analyzed centers had 70% or more measured yields comprising the 0.6-1.8 interval of the my/py ratio. The observance of the 'efficiency' my/py interval assured collection quality control in these centers confirming the reliability of the method," reported scientists.

The authors concluded, "This prediction method generates accurate and immediate yield predictions allowing collection planning and rapid efficiency control.

"As a consequence of our study, four centers out of seven use the described method to plan both leukapheresis number and single-procedure blood processing volume while the remaining three centers plan leukapheresis number on the basis of our predictions, maintaining a fixed single-procedure 200 ml/kg blood volume processing, according to their centre AHSC collection policy."

Pierelli and colleagues published the results of their research in Vox Sanguinis (Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sang, 2006;91(2):126-134).

For additional information, contact L. Pierelli, ASL Viterbo, Osped Belcolle, Service Immunoematol & Trasfus, Strada Sammartinese, I-01100 Viterbo, Italy.

The publisher of the journal Vox Sanguinis can be contacted at: Blackwell Publishing, 9600 Garsington Rd., Oxford OX4 2DQ, Oxon, England.

Keywords: Viterbo, Italy, Collection Efficiency, Leukapheresis, Quality Control, Stem Cell Collection, Yield Prediction.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Keywords: Leukopheresis, CD34+, Apheresis Technologist, Apheresis
Related Glossary Terms: Peripheral Stem Cell Transplants, Stem Cell Transplantation, Stem Cell Transplant, Stem Cell, Peripheral Blood, Autologous Transplant (Auto)
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Risk of leukemia with multiple sclerosis drug higher than thought
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease
Acute Myeloid Leukemia (AML)
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Risk of leukemia with multiple sclerosis drug higher than thought
A miR boost enables acute leukemia cells to mature
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Azerra MAA Accepted by EMEA for CLL
Roche's MabThera approved in Europe for CLL
Chronic Myeloid Leukemia (CML)
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Scientists Gain Insight Into Blood Cancer's Progression
Some blood-system stem cells reproduce more slowly than expected
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
Hodgkin Lymphoma
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Hodgkin lymphoma -- new characteristics discovered
Multiple Myeloma
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Green Tea May Negate the Benefits of Velcade
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Myelodysplastic Syndrome (MDS)
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Non-Hodgkin Lymphoma (NHL)
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Testicular Cancer
Second gene linked to familial testicular cancer
Male Infertility Linked to Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer